nodes	percent_of_prediction	percent_of_DWPC	metapath
Paricalcitol—CYP3A4—Cytarabine—lymphatic system cancer	0.0553	0.318	CbGbCtD
Paricalcitol—CYP3A4—Teniposide—lymphatic system cancer	0.0544	0.313	CbGbCtD
Paricalcitol—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0381	0.219	CbGbCtD
Paricalcitol—CYP3A4—Vincristine—lymphatic system cancer	0.0262	0.151	CbGbCtD
Paricalcitol—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00181	0.00219	CcSEcCtD
Paricalcitol—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.0018	0.00218	CcSEcCtD
Paricalcitol—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.0018	0.00218	CcSEcCtD
Paricalcitol—Anaemia—Bleomycin—lymphatic system cancer	0.0018	0.00218	CcSEcCtD
Paricalcitol—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00179	0.00216	CcSEcCtD
Paricalcitol—Asthenia—Teniposide—lymphatic system cancer	0.00177	0.00214	CcSEcCtD
Paricalcitol—Malaise—Bleomycin—lymphatic system cancer	0.00175	0.00212	CcSEcCtD
Paricalcitol—Pruritus—Teniposide—lymphatic system cancer	0.00174	0.00211	CcSEcCtD
Paricalcitol—Arrhythmia—Carmustine—lymphatic system cancer	0.00174	0.00211	CcSEcCtD
Paricalcitol—Leukopenia—Bleomycin—lymphatic system cancer	0.00174	0.00211	CcSEcCtD
Paricalcitol—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00174	0.0021	CcSEcCtD
Paricalcitol—Cardiac disorder—Vincristine—lymphatic system cancer	0.00173	0.00209	CcSEcCtD
Paricalcitol—Alopecia—Carmustine—lymphatic system cancer	0.00172	0.00209	CcSEcCtD
Paricalcitol—Body temperature increased—Fludarabine—lymphatic system cancer	0.00171	0.00207	CcSEcCtD
Paricalcitol—Mental disorder—Carmustine—lymphatic system cancer	0.00171	0.00207	CcSEcCtD
Paricalcitol—Vaginal infection—Methotrexate—lymphatic system cancer	0.0017	0.00206	CcSEcCtD
Paricalcitol—Malnutrition—Carmustine—lymphatic system cancer	0.0017	0.00206	CcSEcCtD
Paricalcitol—Cough—Bleomycin—lymphatic system cancer	0.0017	0.00206	CcSEcCtD
Paricalcitol—Angiopathy—Vincristine—lymphatic system cancer	0.00169	0.00205	CcSEcCtD
Paricalcitol—Diarrhoea—Teniposide—lymphatic system cancer	0.00169	0.00204	CcSEcCtD
Paricalcitol—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00168	0.00203	CcSEcCtD
Paricalcitol—Chest pain—Bleomycin—lymphatic system cancer	0.00166	0.00201	CcSEcCtD
Paricalcitol—Myalgia—Bleomycin—lymphatic system cancer	0.00166	0.00201	CcSEcCtD
Paricalcitol—Alopecia—Vincristine—lymphatic system cancer	0.00165	0.00199	CcSEcCtD
Paricalcitol—Back pain—Carmustine—lymphatic system cancer	0.00164	0.00199	CcSEcCtD
Paricalcitol—Discomfort—Bleomycin—lymphatic system cancer	0.00164	0.00198	CcSEcCtD
Paricalcitol—Mental disorder—Vincristine—lymphatic system cancer	0.00163	0.00198	CcSEcCtD
Paricalcitol—Chills—Mitoxantrone—lymphatic system cancer	0.00163	0.00197	CcSEcCtD
Paricalcitol—Neoplasm—Methotrexate—lymphatic system cancer	0.00163	0.00197	CcSEcCtD
Paricalcitol—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00162	0.00196	CcSEcCtD
Paricalcitol—Alopecia—Mitoxantrone—lymphatic system cancer	0.0016	0.00194	CcSEcCtD
Paricalcitol—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.0016	0.00194	CcSEcCtD
Paricalcitol—Confusional state—Bleomycin—lymphatic system cancer	0.0016	0.00194	CcSEcCtD
Paricalcitol—Hypersensitivity—Fludarabine—lymphatic system cancer	0.0016	0.00193	CcSEcCtD
Paricalcitol—Oedema—Bleomycin—lymphatic system cancer	0.00159	0.00192	CcSEcCtD
Paricalcitol—Infection—Bleomycin—lymphatic system cancer	0.00158	0.00191	CcSEcCtD
Paricalcitol—Anaemia—Carmustine—lymphatic system cancer	0.00157	0.0019	CcSEcCtD
Paricalcitol—Back pain—Vincristine—lymphatic system cancer	0.00157	0.0019	CcSEcCtD
Paricalcitol—Vomiting—Teniposide—lymphatic system cancer	0.00157	0.0019	CcSEcCtD
Paricalcitol—Sepsis—Methotrexate—lymphatic system cancer	0.00156	0.00189	CcSEcCtD
Paricalcitol—Agitation—Carmustine—lymphatic system cancer	0.00156	0.00189	CcSEcCtD
Paricalcitol—Asthenia—Fludarabine—lymphatic system cancer	0.00155	0.00188	CcSEcCtD
Paricalcitol—Rash—Teniposide—lymphatic system cancer	0.00155	0.00188	CcSEcCtD
Paricalcitol—Dermatitis—Teniposide—lymphatic system cancer	0.00155	0.00188	CcSEcCtD
Paricalcitol—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00155	0.00187	CcSEcCtD
Paricalcitol—Headache—Teniposide—lymphatic system cancer	0.00154	0.00187	CcSEcCtD
Paricalcitol—Pruritus—Fludarabine—lymphatic system cancer	0.00153	0.00186	CcSEcCtD
Paricalcitol—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00153	0.00185	CcSEcCtD
Paricalcitol—Back pain—Mitoxantrone—lymphatic system cancer	0.00153	0.00185	CcSEcCtD
Paricalcitol—Leukopenia—Carmustine—lymphatic system cancer	0.00152	0.00184	CcSEcCtD
Paricalcitol—Anorexia—Bleomycin—lymphatic system cancer	0.00151	0.00183	CcSEcCtD
Paricalcitol—Anaemia—Vincristine—lymphatic system cancer	0.0015	0.00181	CcSEcCtD
Paricalcitol—Agitation—Vincristine—lymphatic system cancer	0.00149	0.0018	CcSEcCtD
Paricalcitol—Hypotension—Bleomycin—lymphatic system cancer	0.00148	0.0018	CcSEcCtD
Paricalcitol—Diarrhoea—Fludarabine—lymphatic system cancer	0.00148	0.00179	CcSEcCtD
Paricalcitol—Hypertension—Carmustine—lymphatic system cancer	0.00147	0.00178	CcSEcCtD
Paricalcitol—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00147	0.00177	CcSEcCtD
Paricalcitol—Nausea—Teniposide—lymphatic system cancer	0.00146	0.00177	CcSEcCtD
Paricalcitol—Anaemia—Mitoxantrone—lymphatic system cancer	0.00146	0.00177	CcSEcCtD
Paricalcitol—Vertigo—Vincristine—lymphatic system cancer	0.00146	0.00176	CcSEcCtD
Paricalcitol—Leukopenia—Vincristine—lymphatic system cancer	0.00145	0.00176	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00145	0.00175	CcSEcCtD
Paricalcitol—Chest pain—Carmustine—lymphatic system cancer	0.00145	0.00175	CcSEcCtD
Paricalcitol—Myalgia—Carmustine—lymphatic system cancer	0.00145	0.00175	CcSEcCtD
Paricalcitol—Anxiety—Carmustine—lymphatic system cancer	0.00144	0.00174	CcSEcCtD
Paricalcitol—Paraesthesia—Bleomycin—lymphatic system cancer	0.00143	0.00173	CcSEcCtD
Paricalcitol—Malaise—Mitoxantrone—lymphatic system cancer	0.00142	0.00172	CcSEcCtD
Paricalcitol—Dyspnoea—Bleomycin—lymphatic system cancer	0.00142	0.00171	CcSEcCtD
Paricalcitol—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00141	0.00171	CcSEcCtD
Paricalcitol—Hypertension—Vincristine—lymphatic system cancer	0.0014	0.0017	CcSEcCtD
Paricalcitol—Confusional state—Carmustine—lymphatic system cancer	0.0014	0.00169	CcSEcCtD
Paricalcitol—Oedema—Carmustine—lymphatic system cancer	0.00139	0.00168	CcSEcCtD
Paricalcitol—Decreased appetite—Bleomycin—lymphatic system cancer	0.00138	0.00167	CcSEcCtD
Paricalcitol—Myalgia—Vincristine—lymphatic system cancer	0.00138	0.00167	CcSEcCtD
Paricalcitol—Cough—Mitoxantrone—lymphatic system cancer	0.00138	0.00167	CcSEcCtD
Paricalcitol—Infection—Carmustine—lymphatic system cancer	0.00138	0.00167	CcSEcCtD
Paricalcitol—Vomiting—Fludarabine—lymphatic system cancer	0.00138	0.00167	CcSEcCtD
Paricalcitol—Rash—Fludarabine—lymphatic system cancer	0.00137	0.00165	CcSEcCtD
Paricalcitol—Dermatitis—Fludarabine—lymphatic system cancer	0.00136	0.00165	CcSEcCtD
Paricalcitol—Hypertension—Mitoxantrone—lymphatic system cancer	0.00136	0.00165	CcSEcCtD
Paricalcitol—Pain—Bleomycin—lymphatic system cancer	0.00136	0.00164	CcSEcCtD
Paricalcitol—Headache—Fludarabine—lymphatic system cancer	0.00136	0.00164	CcSEcCtD
Paricalcitol—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00134	0.00163	CcSEcCtD
Paricalcitol—Chest pain—Mitoxantrone—lymphatic system cancer	0.00134	0.00163	CcSEcCtD
Paricalcitol—Myalgia—Mitoxantrone—lymphatic system cancer	0.00134	0.00163	CcSEcCtD
Paricalcitol—Anxiety—Mitoxantrone—lymphatic system cancer	0.00134	0.00162	CcSEcCtD
Paricalcitol—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00133	0.00161	CcSEcCtD
Paricalcitol—Discomfort—Mitoxantrone—lymphatic system cancer	0.00133	0.00161	CcSEcCtD
Paricalcitol—Oedema—Vincristine—lymphatic system cancer	0.00132	0.0016	CcSEcCtD
Paricalcitol—Anorexia—Carmustine—lymphatic system cancer	0.00132	0.0016	CcSEcCtD
Paricalcitol—Infection—Vincristine—lymphatic system cancer	0.00131	0.00159	CcSEcCtD
Paricalcitol—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00131	0.00158	CcSEcCtD
Paricalcitol—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00131	0.00158	CcSEcCtD
Paricalcitol—Confusional state—Mitoxantrone—lymphatic system cancer	0.0013	0.00157	CcSEcCtD
Paricalcitol—Nervous system disorder—Vincristine—lymphatic system cancer	0.0013	0.00157	CcSEcCtD
Paricalcitol—Hypotension—Carmustine—lymphatic system cancer	0.0013	0.00157	CcSEcCtD
Paricalcitol—Oedema—Mitoxantrone—lymphatic system cancer	0.00129	0.00156	CcSEcCtD
Paricalcitol—Nausea—Fludarabine—lymphatic system cancer	0.00129	0.00156	CcSEcCtD
Paricalcitol—Infection—Mitoxantrone—lymphatic system cancer	0.00128	0.00155	CcSEcCtD
Paricalcitol—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00128	0.00155	CcSEcCtD
Paricalcitol—Shock—Mitoxantrone—lymphatic system cancer	0.00127	0.00154	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00126	0.00153	CcSEcCtD
Paricalcitol—Urticaria—Bleomycin—lymphatic system cancer	0.00126	0.00153	CcSEcCtD
Paricalcitol—Anorexia—Vincristine—lymphatic system cancer	0.00126	0.00153	CcSEcCtD
Paricalcitol—Body temperature increased—Bleomycin—lymphatic system cancer	0.00126	0.00152	CcSEcCtD
Paricalcitol—Insomnia—Carmustine—lymphatic system cancer	0.00125	0.00152	CcSEcCtD
Paricalcitol—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00125	0.00152	CcSEcCtD
Paricalcitol—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00125	0.00151	CcSEcCtD
Paricalcitol—Paraesthesia—Carmustine—lymphatic system cancer	0.00124	0.00151	CcSEcCtD
Paricalcitol—Hypotension—Vincristine—lymphatic system cancer	0.00124	0.0015	CcSEcCtD
Paricalcitol—Dyspnoea—Carmustine—lymphatic system cancer	0.00124	0.0015	CcSEcCtD
Paricalcitol—Somnolence—Carmustine—lymphatic system cancer	0.00123	0.00149	CcSEcCtD
Paricalcitol—Anorexia—Mitoxantrone—lymphatic system cancer	0.00123	0.00149	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00121	0.00146	CcSEcCtD
Paricalcitol—Decreased appetite—Carmustine—lymphatic system cancer	0.00121	0.00146	CcSEcCtD
Paricalcitol—Hypotension—Mitoxantrone—lymphatic system cancer	0.0012	0.00146	CcSEcCtD
Paricalcitol—Insomnia—Vincristine—lymphatic system cancer	0.0012	0.00145	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.0012	0.00145	CcSEcCtD
Paricalcitol—Paraesthesia—Vincristine—lymphatic system cancer	0.00119	0.00144	CcSEcCtD
Paricalcitol—Pain—Carmustine—lymphatic system cancer	0.00119	0.00144	CcSEcCtD
Paricalcitol—Constipation—Carmustine—lymphatic system cancer	0.00119	0.00144	CcSEcCtD
Paricalcitol—Breast disorder—Methotrexate—lymphatic system cancer	0.00118	0.00143	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00117	0.00142	CcSEcCtD
Paricalcitol—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00117	0.00142	CcSEcCtD
Paricalcitol—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00116	0.0014	CcSEcCtD
Paricalcitol—Decreased appetite—Vincristine—lymphatic system cancer	0.00115	0.00139	CcSEcCtD
Paricalcitol—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00115	0.00139	CcSEcCtD
Paricalcitol—Somnolence—Mitoxantrone—lymphatic system cancer	0.00115	0.00139	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00114	0.00138	CcSEcCtD
Paricalcitol—Feeling abnormal—Carmustine—lymphatic system cancer	0.00114	0.00138	CcSEcCtD
Paricalcitol—Fatigue—Vincristine—lymphatic system cancer	0.00114	0.00138	CcSEcCtD
Paricalcitol—Asthenia—Bleomycin—lymphatic system cancer	0.00114	0.00138	CcSEcCtD
Paricalcitol—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00113	0.00137	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00113	0.00137	CcSEcCtD
Paricalcitol—Pain—Vincristine—lymphatic system cancer	0.00113	0.00137	CcSEcCtD
Paricalcitol—Constipation—Vincristine—lymphatic system cancer	0.00113	0.00137	CcSEcCtD
Paricalcitol—Asthma—Methotrexate—lymphatic system cancer	0.00113	0.00137	CcSEcCtD
Paricalcitol—Pruritus—Bleomycin—lymphatic system cancer	0.00112	0.00136	CcSEcCtD
Paricalcitol—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00112	0.00136	CcSEcCtD
Paricalcitol—Fatigue—Mitoxantrone—lymphatic system cancer	0.00111	0.00135	CcSEcCtD
Paricalcitol—Pancreatitis—Methotrexate—lymphatic system cancer	0.00111	0.00134	CcSEcCtD
Paricalcitol—Pain—Mitoxantrone—lymphatic system cancer	0.0011	0.00133	CcSEcCtD
Paricalcitol—Constipation—Mitoxantrone—lymphatic system cancer	0.0011	0.00133	CcSEcCtD
Paricalcitol—Body temperature increased—Carmustine—lymphatic system cancer	0.0011	0.00133	CcSEcCtD
Paricalcitol—Abdominal pain—Carmustine—lymphatic system cancer	0.0011	0.00133	CcSEcCtD
Paricalcitol—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00108	0.00131	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00108	0.00131	CcSEcCtD
Paricalcitol—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00106	0.00129	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00105	0.00128	CcSEcCtD
Paricalcitol—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00105	0.00127	CcSEcCtD
Paricalcitol—Abdominal pain—Vincristine—lymphatic system cancer	0.00105	0.00127	CcSEcCtD
Paricalcitol—Body temperature increased—Vincristine—lymphatic system cancer	0.00105	0.00127	CcSEcCtD
Paricalcitol—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00104	0.00126	CcSEcCtD
Paricalcitol—Urticaria—Mitoxantrone—lymphatic system cancer	0.00102	0.00124	CcSEcCtD
Paricalcitol—Hypersensitivity—Carmustine—lymphatic system cancer	0.00102	0.00124	CcSEcCtD
Paricalcitol—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00102	0.00123	CcSEcCtD
Paricalcitol—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00102	0.00123	CcSEcCtD
Paricalcitol—Pneumonia—Methotrexate—lymphatic system cancer	0.00101	0.00123	CcSEcCtD
Paricalcitol—Vomiting—Bleomycin—lymphatic system cancer	0.00101	0.00122	CcSEcCtD
Paricalcitol—Infestation—Methotrexate—lymphatic system cancer	0.00101	0.00122	CcSEcCtD
Paricalcitol—Infestation NOS—Methotrexate—lymphatic system cancer	0.00101	0.00122	CcSEcCtD
Paricalcitol—Depression—Methotrexate—lymphatic system cancer	0.001	0.00122	CcSEcCtD
Paricalcitol—Rash—Bleomycin—lymphatic system cancer	0.001	0.00121	CcSEcCtD
Paricalcitol—Dermatitis—Bleomycin—lymphatic system cancer	0.001	0.00121	CcSEcCtD
Paricalcitol—Asthenia—Carmustine—lymphatic system cancer	0.000995	0.0012	CcSEcCtD
Paricalcitol—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000979	0.00118	CcSEcCtD
Paricalcitol—Hypersensitivity—Vincristine—lymphatic system cancer	0.000975	0.00118	CcSEcCtD
Paricalcitol—Sweating—Methotrexate—lymphatic system cancer	0.000965	0.00117	CcSEcCtD
Paricalcitol—Epistaxis—Methotrexate—lymphatic system cancer	0.00095	0.00115	CcSEcCtD
Paricalcitol—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00095	0.00115	CcSEcCtD
Paricalcitol—Asthenia—Vincristine—lymphatic system cancer	0.00095	0.00115	CcSEcCtD
Paricalcitol—Diarrhoea—Carmustine—lymphatic system cancer	0.000949	0.00115	CcSEcCtD
Paricalcitol—Nausea—Bleomycin—lymphatic system cancer	0.000943	0.00114	CcSEcCtD
Paricalcitol—Asthenia—Mitoxantrone—lymphatic system cancer	0.000925	0.00112	CcSEcCtD
Paricalcitol—Dizziness—Carmustine—lymphatic system cancer	0.000917	0.00111	CcSEcCtD
Paricalcitol—Diarrhoea—Vincristine—lymphatic system cancer	0.000906	0.0011	CcSEcCtD
Paricalcitol—Pharyngitis—Methotrexate—lymphatic system cancer	0.000897	0.00109	CcSEcCtD
Paricalcitol—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000893	0.00108	CcSEcCtD
Paricalcitol—Urethral disorder—Methotrexate—lymphatic system cancer	0.000886	0.00107	CcSEcCtD
Paricalcitol—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000882	0.00107	CcSEcCtD
Paricalcitol—Vomiting—Carmustine—lymphatic system cancer	0.000881	0.00107	CcSEcCtD
Paricalcitol—Dizziness—Vincristine—lymphatic system cancer	0.000875	0.00106	CcSEcCtD
Paricalcitol—Rash—Carmustine—lymphatic system cancer	0.000874	0.00106	CcSEcCtD
Paricalcitol—Dermatitis—Carmustine—lymphatic system cancer	0.000873	0.00106	CcSEcCtD
Paricalcitol—Headache—Carmustine—lymphatic system cancer	0.000869	0.00105	CcSEcCtD
Paricalcitol—Eye disorder—Methotrexate—lymphatic system cancer	0.000845	0.00102	CcSEcCtD
Paricalcitol—Vomiting—Vincristine—lymphatic system cancer	0.000841	0.00102	CcSEcCtD
Paricalcitol—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000839	0.00102	CcSEcCtD
Paricalcitol—Rash—Vincristine—lymphatic system cancer	0.000834	0.00101	CcSEcCtD
Paricalcitol—Dermatitis—Vincristine—lymphatic system cancer	0.000834	0.00101	CcSEcCtD
Paricalcitol—Headache—Vincristine—lymphatic system cancer	0.000829	0.001	CcSEcCtD
Paricalcitol—Nausea—Carmustine—lymphatic system cancer	0.000823	0.000997	CcSEcCtD
Paricalcitol—Angiopathy—Methotrexate—lymphatic system cancer	0.00082	0.000993	CcSEcCtD
Paricalcitol—Vomiting—Mitoxantrone—lymphatic system cancer	0.000819	0.000992	CcSEcCtD
Paricalcitol—Immune system disorder—Methotrexate—lymphatic system cancer	0.000816	0.000988	CcSEcCtD
Paricalcitol—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000815	0.000986	CcSEcCtD
Paricalcitol—Rash—Mitoxantrone—lymphatic system cancer	0.000813	0.000984	CcSEcCtD
Paricalcitol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000812	0.000983	CcSEcCtD
Paricalcitol—Chills—Methotrexate—lymphatic system cancer	0.000811	0.000982	CcSEcCtD
Paricalcitol—Headache—Mitoxantrone—lymphatic system cancer	0.000807	0.000978	CcSEcCtD
Paricalcitol—Alopecia—Methotrexate—lymphatic system cancer	0.000799	0.000967	CcSEcCtD
Paricalcitol—Mental disorder—Methotrexate—lymphatic system cancer	0.000792	0.000959	CcSEcCtD
Paricalcitol—Malnutrition—Methotrexate—lymphatic system cancer	0.000787	0.000953	CcSEcCtD
Paricalcitol—Nausea—Vincristine—lymphatic system cancer	0.000786	0.000952	CcSEcCtD
Paricalcitol—Dysgeusia—Methotrexate—lymphatic system cancer	0.000771	0.000933	CcSEcCtD
Paricalcitol—Nausea—Mitoxantrone—lymphatic system cancer	0.000766	0.000927	CcSEcCtD
Paricalcitol—Back pain—Methotrexate—lymphatic system cancer	0.000761	0.000921	CcSEcCtD
Paricalcitol—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00073	0.000884	CcSEcCtD
Paricalcitol—Anaemia—Methotrexate—lymphatic system cancer	0.000727	0.00088	CcSEcCtD
Paricalcitol—Malaise—Methotrexate—lymphatic system cancer	0.00071	0.000859	CcSEcCtD
Paricalcitol—Vertigo—Methotrexate—lymphatic system cancer	0.000707	0.000856	CcSEcCtD
Paricalcitol—Leukopenia—Methotrexate—lymphatic system cancer	0.000704	0.000853	CcSEcCtD
Paricalcitol—Cough—Methotrexate—lymphatic system cancer	0.000687	0.000831	CcSEcCtD
Paricalcitol—Chest pain—Methotrexate—lymphatic system cancer	0.00067	0.000811	CcSEcCtD
Paricalcitol—Myalgia—Methotrexate—lymphatic system cancer	0.00067	0.000811	CcSEcCtD
Paricalcitol—Arthralgia—Methotrexate—lymphatic system cancer	0.00067	0.000811	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000665	0.000805	CcSEcCtD
Paricalcitol—Discomfort—Methotrexate—lymphatic system cancer	0.000662	0.000801	CcSEcCtD
Paricalcitol—Confusional state—Methotrexate—lymphatic system cancer	0.000647	0.000784	CcSEcCtD
Paricalcitol—Infection—Methotrexate—lymphatic system cancer	0.000638	0.000772	CcSEcCtD
Paricalcitol—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00063	0.000762	CcSEcCtD
Paricalcitol—Skin disorder—Methotrexate—lymphatic system cancer	0.000624	0.000755	CcSEcCtD
Paricalcitol—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000621	0.000752	CcSEcCtD
Paricalcitol—Anorexia—Methotrexate—lymphatic system cancer	0.000612	0.000741	CcSEcCtD
Paricalcitol—Hypotension—Methotrexate—lymphatic system cancer	0.0006	0.000726	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000585	0.000708	CcSEcCtD
Paricalcitol—Insomnia—Methotrexate—lymphatic system cancer	0.000581	0.000703	CcSEcCtD
Paricalcitol—Paraesthesia—Methotrexate—lymphatic system cancer	0.000577	0.000698	CcSEcCtD
Paricalcitol—Dyspnoea—Methotrexate—lymphatic system cancer	0.000573	0.000693	CcSEcCtD
Paricalcitol—Somnolence—Methotrexate—lymphatic system cancer	0.000571	0.000691	CcSEcCtD
Paricalcitol—Dyspepsia—Methotrexate—lymphatic system cancer	0.000565	0.000684	CcSEcCtD
Paricalcitol—Decreased appetite—Methotrexate—lymphatic system cancer	0.000558	0.000676	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000554	0.000671	CcSEcCtD
Paricalcitol—Fatigue—Methotrexate—lymphatic system cancer	0.000554	0.00067	CcSEcCtD
Paricalcitol—Pain—Methotrexate—lymphatic system cancer	0.000549	0.000665	CcSEcCtD
Paricalcitol—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000529	0.000641	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000525	0.000636	CcSEcCtD
Paricalcitol—Urticaria—Methotrexate—lymphatic system cancer	0.00051	0.000618	CcSEcCtD
Paricalcitol—Abdominal pain—Methotrexate—lymphatic system cancer	0.000508	0.000615	CcSEcCtD
Paricalcitol—Body temperature increased—Methotrexate—lymphatic system cancer	0.000508	0.000615	CcSEcCtD
Paricalcitol—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000473	0.000573	CcSEcCtD
Paricalcitol—Asthenia—Methotrexate—lymphatic system cancer	0.000461	0.000558	CcSEcCtD
Paricalcitol—Pruritus—Methotrexate—lymphatic system cancer	0.000454	0.00055	CcSEcCtD
Paricalcitol—Diarrhoea—Methotrexate—lymphatic system cancer	0.000439	0.000532	CcSEcCtD
Paricalcitol—Dizziness—Methotrexate—lymphatic system cancer	0.000425	0.000514	CcSEcCtD
Paricalcitol—Vomiting—Methotrexate—lymphatic system cancer	0.000408	0.000494	CcSEcCtD
Paricalcitol—Rash—Methotrexate—lymphatic system cancer	0.000405	0.00049	CcSEcCtD
Paricalcitol—Dermatitis—Methotrexate—lymphatic system cancer	0.000405	0.00049	CcSEcCtD
Paricalcitol—Headache—Methotrexate—lymphatic system cancer	0.000402	0.000487	CcSEcCtD
Paricalcitol—Nausea—Methotrexate—lymphatic system cancer	0.000381	0.000462	CcSEcCtD
